Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699293 · ClinicalTrials.gov registry record · Phase 4
NSAIDs vs. Coxibs in the Presence of Aspirin
A Phase 4 study of Cardiovascular Diseases and Rheumatoid Arthritis, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03699293: Recruiting Phase 4 study of Cardiovascular Diseases and Rheumatoid Arthritis, sponsored by Inova Health Care Services.
NCT03699293 is a Phase 4 study of Cardiovascular Diseases and Rheumatoid Arthritis that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 30 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03699293, a Phase 4 study of Cardiovascular Diseases and Rheumatoid Arthritis, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.
Primary Outcome
Percent change in AA-induced platelet aggregation measured by light transmission aggregometry in platelet-rich plasma. Measurements were obtained at: * End of 4-week aspirin 81 mg daily run-in period (baseline) * After completion of the first 4-week treatment period following randomization * After completion of the second 4-week treatment period (crossover period) Aspirin 81 mg daily was administered during the run-in period and continued throughout the study. Each participant received celec
Conditions Studied
Interventions
- DRUG celecoxib 200mg capsule
- DRUG naproxen sodium 550mg tablet
- DRUG Aspirin 81mg tablet
Study Locations (1)
Virginia
- Inova Heart and Vascular Institute - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-09-22 |
| Est. Completion | 2019-11-24 |
| Phase | Phase 4 |
What NCT03699293 shows while recruiting
NCT03699293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions - of which celecoxib 200mg capsule is the first listed.
NCT03699293 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03699293 about?
NCT03699293 is a clinical study titled "NSAIDs vs. Coxibs in the Presence of Aspirin". The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.
What is the current status of trial NCT03699293?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2018-09-22. Estimated completion is 2019-11-24.
What conditions does trial NCT03699293 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Rheumatoid Arthritis.
What interventions are being tested in trial NCT03699293?
The interventions under investigation include: celecoxib 200mg capsule (DRUG), naproxen sodium 550mg tablet (DRUG), Aspirin 81mg tablet (DRUG).
Who is sponsoring clinical trial NCT03699293?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03699293 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03699293's enrollment target sits among peer trials
30 262nd of 300 higher than 33 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI